TY -的T1 sarcoidosi肺移植s: outcome and prognostic factors JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.03358-2020 VL - 58 IS - 2 SP - 2003358 AU - Le Pavec, Jérôme AU - Valeyre, Dominique AU - Gazengel, Pierre AU - Holm, Are M. AU - Schultz, Hans Henrik AU - Perch, Michael AU - Le Borgne, Aurélie AU - Reynaud-Gaubert, Martine AU - Knoop, Christiane AU - Godinas, Laurent AU - Hirschi, Sandrine AU - Bunel, Vincent AU - Laporta, Rosalia AU - Harari, Sergio AU - Blanchard, Elodie AU - Magnusson, Jesper M. AU - Tissot, Adrien AU - Mornex, Jean-François AU - Picard, Clément AU - Savale, Laurent AU - Bernaudin, Jean-François AU - Brillet, Pierre-Yves AU - Nunes, Hilario AU - Humbert, Marc AU - Fadel, Elie AU - Gottlieb, Jens Y1 - 2021/08/01 UR - //www.qdcxjkg.com/content/58/2/2003358.abstract N2 - Study question In patients with sarcoidosis, past and ongoing immunosuppressive regimens, recurrent disease in the transplant and extrapulmonary involvement may affect outcomes of lung transplantation. We asked whether sarcoidosis lung phenotypes can be differentiated and, if so, how they relate to outcomes in patients with pulmonary sarcoidosis treated by lung transplantation.Patients and methods We retrospectively reviewed data from 112 patients who met international diagnostic criteria for sarcoidosis and underwent lung or heart–lung transplantation between 2006 and 2019 at 16 European centres.Results Patient survival was the main outcome measure. At transplantation, median (interaquartile range (IQR)) age was 52 (46–59) years; 71 (64%) were male. Lung phenotypes were individualised as follows: 1) extended fibrosis only; 2) airflow obstruction; 3) severe pulmonary hypertension (sPH) and airflow obstruction; 4) sPH, airflow obstruction and fibrosis; 5) sPH and fibrosis; 6) airflow obstruction and fibrosis; 7) sPH; and 8) none of these criteria, in 17%, 16%, 17%, 14%, 11%, 9%, 5% and 11% of patients, respectively. Post-transplant survival rates after 1, 3, and 5 years were 86%, 76% and 69%, respectively. During follow-up (median (IQR) 46 (16–89) months), 31% of patients developed chronic lung allograft dysfunction. Age and extended lung fibrosis were associated with increased mortality. Pulmonary fibrosis predominating peripherally was associated with short-term complications.Answer to the study question Post-transplant survival in patients with pulmonary sarcoidosis was similar to that in patients with other indications for lung transplantation. The main factors associated with worse survival were older age and extensive pre-operative lung fibrosis.Post-transplant survival in patients with pulmonary sarcoidosis was similar to that in patients with other indications for lung transplantation. The main factors associated with worse survival were older age and extensive pre-operative lung fibrosis. https://bit.ly/2XBfJd6 ER -